BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 29987824)

  • 1. Pulmonary Artery Hypertension Model in Rats by Monocrotaline Administration.
    Bueno-Beti C; Sassi Y; Hajjar RJ; Hadri L
    Methods Mol Biol; 2018; 1816():233-241. PubMed ID: 29987824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.
    Umar S; de Visser YP; Steendijk P; Schutte CI; Laghmani el H; Wagenaar GT; Bax WH; Mantikou E; Pijnappels DA; Atsma DE; Schalij MJ; van der Wall EE; van der Laarse A
    Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1606-16. PubMed ID: 19783775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
    Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: mitochondrial inhibition as driver of cardiac failure?
    Balestra GM; Mik EG; Eerbeek O; Specht PA; van der Laarse WJ; Zuurbier CJ
    Respir Res; 2015 Feb; 16(1):6. PubMed ID: 25645252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of dietary iron restriction on the development of monocrotaline-induced pulmonary vascular remodeling and right ventricular failure in rats.
    Naito Y; Hosokawa M; Hao H; Sawada H; Hirotani S; Iwasaku T; Okuhara Y; Eguchi A; Hirota S; Ohyanagi M; Tsujino T; Masuyama T
    Biochem Biophys Res Commun; 2013 Jun; 436(2):145-51. PubMed ID: 23707944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct right ventricle remodeling in response to pressure overload in the rat.
    Mendes-Ferreira P; Santos-Ribeiro D; Adão R; Maia-Rocha C; Mendes-Ferreira M; Sousa-Mendes C; Leite-Moreira AF; Brás-Silva C
    Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H85-95. PubMed ID: 27199115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
    Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.
    Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L
    Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble guanylate cyclase stimulator, trans-4-methoxy-β-nitrostyrene, has a beneficial effect in monocrotaline-induced pulmonary arterial hypertension in rats.
    Gonzaga-Costa K; Vasconcelos-Silva AA; Rodrigues-Silva MJ; Rebouça CDSM; Duarte GP; Borges RS; Magalhães PJC; Lahlou S
    Eur J Pharmacol; 2021 Apr; 897():173948. PubMed ID: 33609564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats.
    Kanno S; Wu YJ; Lee PC; Billiar TR; Ho C
    Circulation; 2001 Aug; 104(8):945-50. PubMed ID: 11514384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
    J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension.
    Conzatti A; Colombo R; Siqueira R; Campos-Carraro C; Turck P; Luz de Castro A; Belló-Klein A; Sander da Rosa Araujo A
    J Cardiovasc Pharmacol; 2024 Jun; 83(6):612-620. PubMed ID: 38547510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
    Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
    J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
    Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
    Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered mTOR and Beclin-1 mediated autophagic activation during right ventricular remodeling in monocrotaline-induced pulmonary hypertension.
    Deng Y; Wu W; Guo S; Chen Y; Liu C; Gao X; Wei B
    Respir Res; 2017 Mar; 18(1):53. PubMed ID: 28340591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
    Cheng G; Wang X; Li Y; He L
    Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy improves vascular volume in female rats with pulmonary hypertension.
    Lachant DJ; Meoli DF; Haight D; Staicu S; Akers S; Glickman S; Ambrosini R; Champion HC; White RJ
    Am J Physiol Lung Cell Mol Physiol; 2019 Oct; 317(4):L445-L455. PubMed ID: 31322432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
    Adão R; Mendes-Ferreira P; Santos-Ribeiro D; Maia-Rocha C; Pimentel LD; Monteiro-Pinto C; Mulvaney EP; Reid HM; Kinsella BT; Potus F; Breuils-Bonnet S; Rademaker MT; Provencher S; Bonnet S; Leite-Moreira AF; Brás-Silva C
    Cardiovasc Res; 2018 Jul; 114(8):1165-1177. PubMed ID: 29584808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of monocrotaline-induced pulmonary arterial hypertension in rats by rosuvastatin.
    Li XL; Guan RJ; Li JJ
    J Cardiovasc Pharmacol; 2012 Aug; 60(2):219-26. PubMed ID: 22592772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.